Tempus AI (NASDAQ:TEM) Shares Down 2.5% After Insider Selling

Tempus AI, Inc. (NASDAQ:TEM)’s stock price dropped 2.5% on Thursday after an insider sold shares in the company. The company traded as low as $66.29 and last traded at $67.48. Approximately 8,477,029 shares traded hands during mid-day trading, a decline of 24% from the average daily volume of 11,188,259 shares. The stock had previously closed at $69.18.

Specifically, COO Ryan Fukushima sold 20,000 shares of Tempus AI stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $62.50, for a total value of $1,250,000.00. Following the sale, the chief operating officer now owns 962,442 shares of the company’s stock, valued at approximately $60,152,625. This trade represents a 2.04 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Eric P. Lefkofsky sold 82,056 shares of the company’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $58.21, for a total value of $4,776,479.76. Following the sale, the chief executive officer now owns 5,532,987 shares in the company, valued at $322,075,173.27. The trade was a 1.46 % decrease in their position. The disclosure for this sale can be found here. In related news, CEO Eric P. Lefkofsky sold 79,118 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $53.86, for a total value of $4,261,295.48. Following the completion of the sale, the chief executive officer now directly owns 5,692,669 shares in the company, valued at approximately $306,607,152.34. This trade represents a 1.37 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Analyst Ratings Changes

A number of brokerages have recently issued reports on TEM. Stifel Nicolaus cut Tempus AI from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $45.00 to $65.00 in a report on Monday, November 11th. Loop Capital cut their target price on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research report on Tuesday, January 14th. Needham & Company LLC reiterated a “buy” rating and set a $56.00 price target on shares of Tempus AI in a report on Tuesday, January 14th. Guggenheim initiated coverage on shares of Tempus AI in a research report on Monday, December 9th. They set a “buy” rating and a $74.00 price target on the stock. Finally, Piper Sandler restated a “neutral” rating and issued a $70.00 target price (up from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Tempus AI currently has an average rating of “Moderate Buy” and a consensus price target of $58.55.

Tempus AI Price Performance

The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The business’s fifty day moving average is $44.36 and its 200-day moving average is $48.84.

Institutional Investors Weigh In On Tempus AI

Large investors have recently modified their holdings of the stock. First Horizon Advisors Inc. bought a new position in Tempus AI during the third quarter worth about $30,000. Geode Capital Management LLC grew its position in Tempus AI by 0.4% during the third quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock worth $7,537,000 after buying an additional 539 shares in the last quarter. FNY Investment Advisers LLC purchased a new position in shares of Tempus AI during the fourth quarter worth about $67,000. IFP Advisors Inc bought a new position in shares of Tempus AI in the 4th quarter worth $76,000. Finally, US Bancorp DE purchased a new stake in Tempus AI during the fourth quarter valued at about $80,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.